Helen Zaltsman, MD
Internal Medicine · Brooklyn, NYNPI 1104819010
Payments from drug & device makers
Across 95 payments — averaging $48.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardinal Health 110 LLC$2K
- AbbVie$777
- Lilly USA, LLC$270
- GSK$230
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$128
- Novo Nordisk$128
- plus $1K from 21 others
What the payments were for
- Consulting fees$2,00044%
- Food & beverage$2,56156%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardinal Health 110 LLC | 1 | $2,000 |
| AbbVie(2 entities) | 24 | $777 |
| Lilly USA, LLC | 8 | $270 |
| GSK | 6 | $230 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $128 |
| Novo Nordisk | 6 | $128 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Antares Pharma, Inc. | 1 | $102 |
| Nestle Healthcare Nutrition Inc. | 5 | $88 |
| Merck | 5 | $73 |
| Amarin Pharma, Inc. | 3 | $71 |
| Novartis | 3 | $67 |
| AstraZeneca | 4 | $63 |
| Amgen | 3 | $63 |
| Ironwood Pharmaceuticals, Inc | 3 | $56 |
| Pfizer | 2 | $46 |
| Astellas Pharma US Inc | 2 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Smith+Nephew | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $25 |
| Ardelyx, Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Heartflow, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,561 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 233 | $72,698 |
| JanuviaSitagliptin Phosphate | 102 | $55,946 |
| Dihydroergotamine Mesylate | 50 | $51,531 |
| EliquisApixaban | 69 | $40,665 |
| CreonLipase/Protease/Amylase | 41 | $39,641 |
| VascepaIcosapent Ethyl | 101 | $32,265 |
| TrulicityDulaglutide | 22 | $24,043 |
| Dexlansoprazole DrDexlansoprazole | 95 | $19,376 |
| Cyclosporine | 19 | $18,040 |
| LinzessLinaclotide | 22 | $15,043 |
| Icosapent Ethyl | 88 | $14,182 |
| EntrestoSacubitril/Valsartan | 19 | $11,995 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $9,474 |
| TrulancePlecanatide | 15 | $8,689 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $73 | $65,420118 claims |
| AbbVieCreon, Linzess, Synthroid | $777 | $56,507102 claims |
| PfizerEliquis | $46 | $40,66569 claims |
| Lilly USA, LLCTrulicity | $270 | $24,04322 claims |
| NovartisEntresto | $67 | $11,99519 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $128 | $8,68915 claims |
| GSKBreo Ellipta | $230 | $6,69417 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $36 | $630110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.